Chemomab Therapeutics (CMMB) Earnings Date, Estimates & Call Transcripts → What President Biden's new law means for investors (From Stansberry Research) (Ad) Free CMMB Stock Alerts $0.83 -0.03 (-3.48%) (As of 10:50 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 12EstimatedActual EPS (Mar. 7) -$0.26 Beat By $0.14 Consensus EPS (Mar. 7) -$0.40 Read Call Transcript Get Chemomab Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CMMB and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCMMB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CMMB Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. Chemomab Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.02)($0.02)($0.02)Q2 20241($0.02)($0.02)($0.02)Q3 20241($0.02)($0.02)($0.02)Q4 20241($0.02)($0.02)($0.02)FY 20244($0.08)($0.08)($0.08)CMMB Earnings Date and InformationChemomab Therapeutics last announced its quarterly earnings results on March 7th, 2024. The reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.14. Chemomab Therapeutics has generated ($1.60) earnings per share over the last year (($1.60) diluted earnings per share). Earnings for Chemomab Therapeutics are expected to remain at ($0.90) per share in the coming year. Chemomab Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off prior year's report dates.Read More Chemomab Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/12/2024(Estimated)------- 3/7/2024Q4 2023($0.40)($0.26)+$0.14($0.26)-- 11/9/2023Q3 2023($0.60)($0.34)+$0.26($0.34)--8/14/2023Q2 2023($0.80)($0.72)+$0.08($0.72)--5/11/2023Q1 2023($0.80)($0.80)-($0.80)--3/20/2023Q4 2022($0.80)($0.72)+$0.08($0.72)--11/11/2022Q3 2022($0.60)($0.70)($0.10)($0.70)-- Get the Latest News and Ratings for CMMB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2022Q2 2022($0.60)($0.54)+$0.06($0.54)--5/12/2022Q1 2022($0.40)($0.44)($0.04)($0.44)--3/9/2022Q4 2021($0.40)($0.44)($0.04)($0.44)--11/11/2021Q3 2021($0.02)($0.26)($0.24)($0.26)--8/12/2021Q2 2021($0.27)($0.26)+$0.01($0.26)--5/12/2021Q1 2021($0.43)($0.22)+$0.21($0.22)--3/9/2021Q4 2020($8.00)($4.00)+$4.00($4.00)--11/16/2020Q3 2020($7.20)($5.60)+$1.60($5.60)--8/14/2020Q2 2020($8.80)($7.20)+$1.60($7.20)--5/7/2020Q1 2020($8.80)($6.56)+$2.24($5.12)--3/17/2020Q4 2019($2.08)$31.84+$33.92$40.48--11/15/2019Q3 2019($2.40)($36.16)($33.76)($36.16)--8/5/2019Q2 2019($12.48)($4.00)+$8.48($4.00)--5/22/2019Q1 2019-($56.00)($56.00)($56.00)-- Chemomab Therapeutics Earnings - Frequently Asked Questions When is Chemomab Therapeutics's earnings date? Chemomab Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates. Learn more on CMMB's earnings history. Did Chemomab Therapeutics beat their earnings estimates last quarter? In the previous quarter, Chemomab Therapeutics (NASDAQ:CMMB) reported ($0.26) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.40) by $0.14. Learn more on analysts' earnings estimate vs. CMMB's actual earnings. How can I read Chemomab Therapeutics's conference call transcript? The conference call transcript for Chemomab Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Chemomab Therapeutics generate each year? Chemomab Therapeutics (NASDAQ:CMMB) has a recorded net income of -$24.22 million. CMMB has generated -$1.60 earnings per share over the last four quarters. What is Chemomab Therapeutics's EPS forecast for next year? Chemomab Therapeutics's earnings are expected to stay at ($0.90) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Molecular Templates Earnings NuCana Earnings Galera Therapeutics Earnings Addex Therapeutics Earnings Aeterna Zentaris Earnings Guardion Health Sciences Earnings Moleculin Biotech Earnings MIRA Pharmaceuticals Earnings Avalo Therapeutics Earnings Elevai Labs Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?JD’s Earnings Could Mean Chinese Stocks Making a ComebackHome Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-Turn This page (NASDAQ:CMMB) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
